Achieving clinical success with BET inhibitors as anti-cancer agents.

Br J Cancer · 2021 · PMC8076232 · PMID 33723398

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

A small clinical trial showed a trend for both MYC repression and an increase in HEXIM1 in the plasma of patients treated with the BETi BAY1238097 for mixed, refractory malignancies. 61 This trend was observed when plasma concentrations of the BETi reached approximately 20 μg/l or greater.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.